Oncolytic Vaccinia Virus Combination Cancer Therapy


Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.

Download PDF
Document Preview
Document History
  • Publication: Mar 17, 2011
  • Application: Sep 14, 2010
    WO US 2010/0048829 W
  • Priority: Sep 21, 2009
    US US 24425009 P
  • Priority: Sep 14, 2009
    US US 24223809 P

Download Citation

Sign in to the Lens